Ember Therapeutics is a biopharmaceutical company dedicated to the clinical application of bone morphogenetic protein-7. It develops regenerative medicines for the disease modification of osteoarthritis, the reversal of insulin resistance, the inhibition and reversal of organ fibrosis in diseases such as chronic kidney disease and Alport syndrome, as well as metabolic diseases, including obesity and type 2 diabetes.